EIS — iShares MSCI Israel ETF
Price when we picked it (Jun 16, 2026)
$125.61
P/E Ratio
—
P/E Forward
—
Dividend
1.14%
Market Cap
$1.03B
EPS
—
Consensus
ETF — index basket (no individual rating)
What they do
iShares MSCI Israel ETF (NYSE Arca: EIS) is an exchange-traded fund (ETF), not an individual company. An ETF is a basket of many stocks packaged into a single instrument you buy and sell like a stock. It's issued by iShares (BlackRock).
What it holds: it tracks the MSCI Israel index, which groups the large- and mid-cap companies of Israel (~129 companies, ~85% of the country's investable market).
Its biggest positions (top 10, ~Jun 2026):
- Teva Pharmaceutical (pharma) ~8.8%
- Bank Leumi (bank) ~8.0%
- Bank Hapoalim (bank) ~7.0%
- Tower Semiconductor (chips) ~6.9%
- Elbit Systems (defense) ~5.4%
- Nova (chip equipment) ~3.4%, Phoenix Financial (insurance) ~3.3%, Enlight Renewable Energy ~3.2%, Israel Discount Bank ~3.0%, Mizrahi Tefahot Bank ~2.6%
The dominant themes: banking (Leumi, Hapoalim, Discount, Mizrahi add up to ~20% of the fund), health (Teva), semiconductors (Tower, Nova) and defense (Elbit) — the heart of the 'startup nation'.
Costs and income: it charges an expense ratio of 0.59% a year and pays a modest dividend of ~1.1% a year (semi-annual distribution), which comes from the dividends of the Israeli companies it holds. Assets (AUM): ~$1.0 billion.
Why it enters the portfolio: even though it's a basket and not a single company, it also pays dividends — it fits the 'own things that pay you' thesis — and gives diversified exposure to a developed, resilient and very tech-heavy economy for a reasonable fee. It also reinforces today's pick: Bank Hapoalim lives inside this fund.
Why we like it
EIS at $125.61 is the simplest, most diversified way to get exposure to Israel — the 'startup nation' — in a single buy, without depending on one company. Specific reasons:
- Exposure to the whole Israeli economy at once: solid, cheap banks (Leumi, Hapoalim, Discount, Mizrahi ~20% of the fund), the world's largest generics pharma (Teva), chipmakers (Tower, Nova) and defense champion Elbit — one buy gives you finance, health, semiconductors and defense.
- Proven resilience: despite years of geopolitical tension and war in the region, the Israeli market has been surprisingly resilient — it's a developed economy, not a fragile emerging market.
- Defense theme with a tailwind: Elbit Systems and the Israeli defense ecosystem benefit from rising global military spending.
- Reasonable fee (0.59%) and it pays you dividends (~1.1%): unlike betting on a single company, this basket distributes the dividend from its ~129 companies, twice a year.
- Real diversification: instead of picking one bank or one Israeli tech name, you hold the biggest ones in a single instrument.
- Synergy with the portfolio: today we also bought Bank Hapoalim separately — EIS gives you that bank PLUS the rest of Israel. It's country exposure, diversified and with some income.
Key Risk
Risks:
- Geopolitical risk — #1: Israel sits in one of the world's most conflict-prone regions; a war or escalation (with Iran, Gaza, Lebanon) can hit the whole market at once and without warning. It's the risk that defines this ETF.
- Currency risk (the shekel): the ETF trades in dollars but its stocks are in Israeli shekels; if the shekel weakens against the dollar, your return drops even if the stocks rise locally.
- Concentration: the 10 largest names are more than half the fund, and a single sector (banking) weighs ~20% — it's not 'infinitely diversified Israel'.
- Dependence on Teva: the biggest position is Teva (~8.8%), a pharma with a lot of historical debt and exposed to the generics price war; if it stumbles, the fund feels it.
- Modest dividend (~1.1%): it pays less than our other ETFs (FLKR ~2%, EZA ~6%) — the thesis here is exposure + resilience, not high income.
- No 'active management': an ETF tracks the index blindly — if the index is heavy in banking or in Teva, you carry that imbalance.
This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.
Vectorial Data picked EIS on Jun 16, 2026 at $125.61.
Full Research
iShares MSCI Israel ETF (EIS) — Full Research
Price: $125.61 | Type: ETF | Expense ratio: 0.59% | Div Yield: ~1.1% | AUM: ~$1.0B USD
⚠️ This is an ETF, not a company
EIS is a basket of ~129 large- and mid-cap Israeli companies packaged into a single instrument. It has no CEO and no single business: it's diversified exposure to a country. Issuer: iShares (BlackRock). Index: MSCI Israel.
What it holds (top 10, ~Jun 2026)
| # | Company | Sector | Weight |
|---|---|---|---|
| 1 | Teva Pharmaceutical | Health (generics) | 8.8% |
| 2 | Bank Leumi | Bank | 8.0% |
| 3 | Bank Hapoalim | Bank | 7.0% |
| 4 | Tower Semiconductor | Chips | 6.9% |
| 5 | Elbit Systems | Defense | 5.4% |
| 6 | Nova | Chip equipment | 3.4% |
| 7 | Phoenix Financial | Insurance | 3.3% |
| 8 | Enlight Renewable Energy | Renewables | 3.2% |
| 9 | Israel Discount Bank | Bank | 3.0% |
| 10 | Mizrahi Tefahot Bank | Bank | 2.6% |
Top 10 ≈ 51% of the fund. Banking alone (Leumi + Hapoalim + Discount + Mizrahi) ≈ 20%.
Dominant themes
| Theme | Names |
|---|---|
| Banking (~20%) | Leumi, Hapoalim, Discount, Mizrahi |
| Health | Teva (the world's largest generics maker) |
| Semiconductors | Tower, Nova |
| Defense | Elbit Systems |
Key data
| Metric | Value |
|---|---|
| Expense ratio | 0.59% /year |
| Dividend yield (TTM) | ~1.1% (semi-annual distribution) |
| AUM | ~$1.0 billion |
| No. of holdings | ~129 |
Anchor Fact
Buying EIS is buying the heart of the 'startup nation' in a single trade: its four big banks, its pharma giant Teva, its chipmakers (Tower, Nova) and its defense champion Elbit. And despite living in one of the planet's most conflict-prone regions, the Israeli market has historically been resilient — it's a developed economy, not a fragile emerging one. Fun fact: Bank Hapoalim, our other pick today, is the fund's third-largest position.
Top Risks
- Geopolitical — a regional war/escalation can hit everything at once
- Currency (shekel) — trades in USD, holdings in shekels
- Concentration — top 10 ≈ 51%, banking ≈ 20%
- Dependence on Teva — biggest position, historical debt + generics
- Modest dividend (~1.1%) — less than FLKR/EZA
Why does it enter the portfolio?
Even though it's a basket and not a single company, it also pays dividends (~1.1%), fits the 'own things that pay you' thesis, and gives cheap (0.59%) diversified exposure to a developed, tech-heavy and resilient economy. It also reinforces today's pick: Bank Hapoalim lives inside the fund.
Thesis in one line
The simplest way to get exposure to Israel — its banking, Teva, its chips and its defense — in a single buy, for a 0.59% fee and with some dividend, betting on the resilience of a developed economy in a tough region.
Research date: 16 Jun 2026 | Next review: Dec 2026
This is not financial advice.
More picks in ETF
- VGK — Vanguard FTSE Europe ETF
- VPL — Vanguard FTSE Pacific ETF
- TUR — iShares MSCI Turkey ETF
- FLKR — Franklin FTSE South Korea ETF
- EZA — iShares MSCI South Africa ETF
- XLE — Energy Select Sector SPDR Fund
More picks from Israel
See all picks from Israel →This is not financial advice. Consult a certified financial advisor.
The author may hold positions in the securities discussed.
Past performance does not guarantee future results.